JUPITER Halted: Rosuvastatin Significantly Reduces Cardiovascular Morbidity and Mortality

March 31, 2008

March 31, 2008 (Chicago, IL)Rosuvastatin gained clinical traction today with the announcement that a large event-driven study was stopped early because the lipid-lowering agent was shown to be more beneficial than placebo in reducing cardiovascular morbidity and mortality [1].

The study is known as the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), a large, multinational, long-term, double-blind, placebo-controlled, randomized clinical trial designed to assess directly whether statin therapy (rosuvastatin 20 mg/day) should be given to apparently healthy individuals with low LDL-cholesterol levels but elevated C-reactive-protein (CRP) levels.

The halting of JUPITER was announced in the wake of the presentation of the disappointing results of the Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) study and an American College of Cardiology consensus panel that urged physicians to prescribe statin medications with proven clinical effectiveness. AstraZeneca issued a press release saying the independent data monitoring board observed "unequivocal evidence of a reduction in cardiovascular morbidity and mortality" among those treated with rosuvastatin compared with placebo.

In total, the trial included 15 000 males aged 50 years and older and females aged 60 years and older with no history of MI, stroke, or arterial revascularisation and LDL-cholesterol levels <130 mg/dL. Patients were considered at risk for coronary heart disease on the basis on their elevated CRP levels. The lead investigator of JUPITER is Dr Paul Ridker (Brigham and Women's Hospital, Boston, MA).

AstraZeneca sponsored the JUPITER study.

  1. AstraZeneca. Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit [press release]. March 31, 2008. Available at: http://www.astrazeneca.com/pressrelease/5385.aspx .

The complete contents of Heartwire , a professional news service of WebMD, can be found at www.theheart.org, a Web site for cardiovascular healthcare professionals.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.